Skin redness and other symptoms associated with rosacea were found to improve with the use of a skincare regimen formulated for the treatment of centrofacial erythema.
An extension study finds that a novel topical minocycline foam is safe and well tolerated for the treatment of rosacea for up to 52 weeks.
Current smoking status is associated with a lower risk for rosacea, a study finds.
Hypertension and dyslipidemia display a correlation with rosacea, although ischemic heart disease, stroke, and diabetes do not.
The microbial diversity and relative abundance of bacterial taxa in acne patients and rosacea patients reveal species significantly enriched in rosacea and not acne.
A glycolic and salicylic acid combination serum is presented as a treatment option for patients rejecting prescription medications.
Patients with rosacea possess serum bilirubin and uric acid levels that differ from those found in healthy patients, a novel study finds.
An update to rosacea treatment guidelines provides a comprehensive summary of management options, including expert evaluations–based on the phenotypes of each patient–to serve as a guide for tailoring treatment and care.
FMX103 1.5%, a novel topical minocycline foam, proves to be a respectable choice for treatment of moderate to severe papulopustular rosacea.
Compelling evidence supports IVM 1% cream as an effective topical treatment for papulopustular rosacea, that improves QoL over time.
